We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Telomerase Reverse Transcriptase Protein Expression Evaluated for Melanomas

By LabMedica International staff writers
Posted on 19 Jul 2021
Print article
Image: Telomerase reverse transcriptase (TERT) expression in non-lentiginous acral melanoma (NLAM) and non-acral cutaneous melanoma (NACM): (A) exhibiting 1+ TERT staining intensity and (B) The intensity of TERT expression and proportion of TERT-positive cells could also vary in cutaneous melanomas (Photo courtesy of MD Anderson Cancer Center)
Image: Telomerase reverse transcriptase (TERT) expression in non-lentiginous acral melanoma (NLAM) and non-acral cutaneous melanoma (NACM): (A) exhibiting 1+ TERT staining intensity and (B) The intensity of TERT expression and proportion of TERT-positive cells could also vary in cutaneous melanomas (Photo courtesy of MD Anderson Cancer Center)
Telomeres are regions of repetitive nucleotide sequences located at the ends of chromosomes that play a key role in the maintenance of genomic integrity and stability in cells. In normal nonneoplastic somatic cells, telomeres progressively shorten with successive cell divisions.

Molecularly distinct from cutaneous melanomas arising from sun-exposed sites, acral lentiginous melanomas (ALMs) typically lack ultraviolet-signature mutations, such as telomerase reverse transcriptase (TERT) promoter mutations. Instead, ALMs show a high degree of copy number alterations, often with multiple amplifications of TERT, which are associated with adverse prognosis.

Pathologists at the University of Texas MD Anderson Cancer Center (Houston, TX, USA) identified a total of 57 cases of acral and non-acral melanocytic lesions, including 24 primary ALMs, six metastatic ALMs, 10 primary non-lentiginous acral melanomas (NLAMs), 12 primary NACMs, and five acral nevi (AN), diagnosed at their institution between 2003 and 2016. Demographic, clinical, and histopathologic parameters and follow-up data for the selected cases were retrieved through review of the final pathology reports and clinical charts.

Immunohistochemical (IHC) analysis of TERT protein expression was performed on a 5-μm–thick paraffin section was cut from each tissue block of selected cases. The paraffin sections were then tested for TERT protein expression by IHC using an anti-TERT monoclonal rabbit anti-human antibody (Abcam, Cambridge, MA, USA) performed on a Leica Bond autostainer (Leica Biosystems, Buffalo Grove, IL, USA) per routine laboratory protocols. The pattern of TERT protein expression was recorded as negative, cytoplasmic, nuclear, or Golgi/perinuclear.

The investigators reported that TERT expression was more frequent in ALMs than in non-lentiginous acral melanomas and non-acral cutaneous melanomas, and was absent in acral nevi. When present, TERT expression in ALMs was cytoplasmic and more intense than TERT expression in other melanocytic lesions (with a higher H-score). There was a trend toward decreased overall survival in patients with ALMs with TERT immunoreactivity, but it did not reach statistical significance. Furthermore, no correlation was found between TERT expression and disease-specific survival in patients with ALMs.

The authors concluded that their study demonstrated that unlike TERT promoter mutations, TERT protein expression was frequently detected in both primary and metastatic ALMs. In addition, the study was the first to demonstrate differences in TERT immunohistochemical expression between ALMs and NLAMs, which have never been separately studied but rather have been grouped together (i.e., as “acral melanomas”) without histologic distinction. Lastly, in their study, although TERT expression was more frequent and of stronger intensity in ALMs than in other types of melanocytic lesions, with higher overall H-scores, TERT immunoreactivity in ALMs did not correlate with survival. The study was published in the July 2021 issue of the journal Archives of Pathology and Laboratory Medicine.

Related Links:
University of Texas MD Anderson Cancer Center
Abcam
Leica Biosystems


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.